Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Results from previous phase 3 trials showed riskankizumab outperformed J&J’s Stelara (ustekinumab), an IL-12 and IL-23 blocker, and Humira against the PASI 90 and sPGA (0/1) measures in psoriasis.

Two of the studies also evaluated the biologic agent adalimumab (Humira, Abbvie ... the Psoriasis Area and Severity Index (PASI) 75 and the Health Assessment Questionnaire Disability Index ...